From: "April
Date: Fri Jul 19 1996 - 08:46:27 EST
We have just begun a pilot study with TPO in breast-Ca and are currently using a three color panel of CD41FITC(BD), CD90PE(PharMingen) and CD34PerCP(BD) to define the mega. The major problem is to be sure that you are not identifying platelets attached to cells. I would recommed the use of ACD-A as an anticoagulant to reduce the 'platelet stickiness'; and you might want to include CD62 for activated platelets and a marker to ensure that the CD41+ are not attached to monocytes or granulocytes. We are using a 50,000 event live gate in the lowSSC and the majority of the CD41+CD34+THYdim cells are in a region just above the lymphocytes and in our normal GCSF stimulated donors this represents approx 0.06% total cells. Good Luck , April April G. Durett Technology Transfer- Flow Cytometry (R8.1421) Blood-Marrow Transplantation (Box 024) The University of Texas MD Anderson Cancer Center 1515 Holcombe Blvd Houston TX 77030 Lab/Voice (713)7924367 FAX (713)794-4902
This archive was generated by hypermail 2.1.6 : Thu Jan 01 2004 - 17:31:26 EST
